tirzepatide cvot SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of In patients with type 2
Pay in 4 interest-free payments of $6.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Live Spec
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS CVOT trial results: https: nej.md 4qd5rLx Long awaited SURPASS CVOT: Cardiovascular Outcomes with Tirzepatide vs Dulaglutide in NEJM: #tirzepatide noninferior to #dulaglutide for 3 point MACE in T2D with ASCVD, with greater improvements in weight, A1c, BP, triglycerides, and kidney function. Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS CVOT Key milestones of tirzepatide in the treatment of diabetes, obesity and Download Scientific Diagram Diabetes Distilled: SURPASS CVOT Tirzepatide demonstrates cardiovascular benefit in secondary prevention DiabetesontheNet SURPASS CVOT shows tirzepatide delivers comparable cardiovascular safety to dulaglutide in patients with type 2 diabetes and established ASCVD, reinforcing the shift toward therapies that optimize whole cardiometabolic systems. As outcome datasets grow
Store: www.allread.ai · Domain: www.allread.ai








.png)




















